United States Department of Defense
1400 Defense Pentagon, Room 1E757
Washington
D.C.
20301-1400
Tel: 703-697-5737
Website: http://www.defenselink.mil/
48 articles about United States Department of Defense
-
Factor Bioscience Announces U.S. Department of Defense Grant to Develop Gene-Edited Cell Therapies
1/9/2024
Factor Bioscience Inc. announced the award of a U.S. Department of Defense grant to develop next-generation cell therapy candidates using Factor's patented mRNA, cell-reprogramming, and gene-editing technologies.
-
Codagenix Receives Additional Award from US Department of Defense to Advance Development of Dengue Vaccine
10/24/2023
Codagenix Inc. today announced that the US Department of Defense (DoD), through the US Army Medical Research and Development Command and the US Army Medical Research Acquisition Activity, has awarded the Company $5.88 million to advance the development of its CodaVax-DENV, a tetravalent live attenuated dengue vaccine program.
-
Lumen Bioscience awarded $16.2 million in DoD funding to advance LMN-201 through late-stage trials
10/17/2023
Lumen Bioscience—a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, announced it was awarded $16.2 million by the U.S. Department of Defense to advance LMN-201 through late-stage trials.
-
U.S. Department of Defense Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure
7/18/2023
Kaléo announced their selection by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical to develop a reconstitution auto-injector device that delivers atropine, the Reconstitution Auto-Injector Device – Atropine.
-
Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program
7/5/2023
Evotec SE announced that the U.S. Department of Defense has awarded Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid development of monoclonal antibody -based drug product prototypes targeting orthopoxviruses.
-
Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection
5/17/2023
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, announced that it had won an award from the U.S. Defense Innovation Unit, a division of the U.S. Department of Defense, for ‘Exhaled Breath Diagnostics’.
-
Lumen Bioscience Awarded $8.8 million from U.S. Department of Defense to Develop Fast-Acting, Intranasal Countermeasure Against Respiratory Viruses
5/11/2023
Lumen Bioscience today announced a new $8.8 million project funded by the U.S. Department of Defense (DOD) to develop and test a prototype broad-spectrum, fast-acting intranasal powder for treatment and prevention of known and emerging viral respiratory infections.
-
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine
12/23/2022
Bavarian Nordic A/S announced a new agreement with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, for the advanced development of MVA-BN® WEV, a prophylactic vaccine candidate against Western, Eastern and Venezuelan equine encephalitis virus, which can cause a rare, but potentially deadly mosquito-borne illness in humans.
-
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease
12/22/2022
INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease in concert with Virgina Commonwealth University (VCU) and Barrow Neurological Institute have received a grant from the Department of Defense.
-
Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate
11/2/2022
Cerus Corporation announced that it has been awarded a $9.1 million contract by the U.S. Department of Defense Industrial Base Analysis and Sustainment program for the development of pathogen reduced, lyophilized cryoprecipitate to treat bleeding due to trauma.
-
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®- In 2022
9/29/2022
SIGA Technologies, Inc. today announced that the U.S. Department of Defense (DoD) awarded a new contract to SIGA for the procurement of up to $10.7 million of oral TPOXX.
-
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens
9/15/2022
GigaGen Inc. announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.
-
Codagenix Announces Award with the US Department of Defense for Development of Balanced, Tetravalent Dengue Vaccine
8/17/2022
Codagenix Inc. today announced the Department of Defense has granted the company a $4.4 million award to progress development of CodaVax-DENV, its next-generation tetravalent dengue vaccine candidate.
-
Most money moves happened in Europe this week, including a government-backed award for Parkinson’s disease research and seed funding for an RNA platform.
-
Monday, Moderna told a Delaware federal court that it was immune from patent-infringement charges over the COVID-19 vaccine because it supplied the vaccine for a U.S. government effort.
-
Ventus Therapeutics Awarded Grant by the U.S. Department of Defense to Study the Role of cGAS in Lupus
5/9/2022
Ventus Therapeutics, Inc. announced today that it has been awarded a Lupus Research Program Idea Award from the U.S. Department of Defense (DoD).
-
Partner Therapeutics Announces Contract with U.S. Department of Defense for Advanced Development of Leukine® to Treat Sulfur Mustard Gas (HD) Exposure
2/17/2022
Partner Therapeutics, Inc. (PTx) today announced a milestone-based Other Transaction Agreement (OTA) with the United States Department of Defense (DoD) to fund development and regulatory activities to support an sBLA of Leukine.
-
Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin Treatment
2/9/2022
National Resilience, Inc. today announced the U.S. Department of Defense (DOD) has awarded Ology Bioservices, Inc. (Ology), a wholly owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxin.
-
Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)
7/7/2021
Ischemix, Inc., a private company focused on developing therapeutics for serious medical conditions, announced that the US Department of Defense has made a $2.9 award to the Company to fund a Phase 1 study of CMX-2043, a novel compound for the treatment of acute TBI.
-
Ellume Announces $231.8 Million Agreement with the U.S. Government to Scale Up Production of COVID-19 Home Tests
2/1/2021
The investment will support the establishment of Ellume’s first U.S. manufacturing facility, increasing Ellume’s global production capacity by 500,000+ tests per day once completed